/PRNewswire/ Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months.
/PRNewswire/ Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months.
If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis
There are approximately 160,000 patients in the U.S. living with eosinophilic. | April 4, 2022
/PRNewswire/ Dupixent significantly reduced itch at 12 weeks, and at 24 weeks nearly three times as many Dupixent patients experienced clinically meaningful.
/PRNewswire/ Dupixent 300 mg weekly is the only biologic medicine to show positive, clinically meaningful Phase 3 results in adults and adolescents with.